ISCOM-based equine influenza vaccine: Duration of immunity and randomised clinical trials to assess an accelerated schedule of immunisation and efficacy  by Paillot, R. et al.
Trials in Vaccinology 4 (2015) 61–70Contents lists available at ScienceDirect
Trials in Vaccinology
journal homepage: www.elsevier .com/locate / t r ivacISCOM-based equine inﬂuenza vaccine: Duration of immunity and
randomised clinical trials to assess an accelerated schedule of
immunisation and efﬁcacyhttp://dx.doi.org/10.1016/j.trivac.2015.07.002
1879-4378/ 2015 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abbreviations: RT, rectal temperature; CMI, cell-mediated immunity; EI, equine
inﬂuenza; EID50, 50% egg infectious dose; EIV, equine inﬂuenza virus; IFN,
interferon; ISCOM, Immuno-Stimulating COMplex; OIE, Ofﬁce International des
Epizooties or World Organisation for Animal Health; SRH, single radial haemolysis;
ToBI, tetanus toxin-binding inhibition; TT, tetanus toxoid; V, vaccination.
⇑ Corresponding author.
E-mail address: romain.paillot@aht.org.uk (R. Paillot).R. Paillot a,⇑, S. Fraser b, L. Prowse-Davis a, N. Rash a, F. Montesso a, N. Slootmans c, A. Thomas c,
B. Besognet d, T. Meinert e, E. Ons c, J. Salt c
aAnimal Health Trust, Centre for Preventive Medicine, Lanwades Park, Newmarket, Suffolk CB8 7UU, UK
bMoredun Scientiﬁc Ltd, Pentlands Science Park, Bush Loan, Penicuik, Midlothian EH26 0PZ, UK
c Zoetis, Veterinary Medicine Research and Development, Mercuriusstraat 20, B-1930 Zaventem, Belgium
d Zoetis, 23-25 Avenue du Dr Lannelongue, 75014 Paris, France
e Zoetis, 333 Portage Street, Kalamazoo, 49007 MI, USA
a r t i c l e i n f oArticle history:
Received 4 February 2015
Revised 15 July 2015
Accepted 18 July 2015
Available online 29 July 2015
Keywords:
Equine inﬂuenza
Vaccine
ISCOM
Protection
Horsea b s t r a c t
The widespread use of equine inﬂuenza (EI) vaccines plays an important role in the prevention and
control of EI outbreaks. Vaccine strain updates, optimisation of immunisation schedules, and frequent
evaluation of vaccine efﬁcacy are necessary to maintain an acceptable level of protection and overall
disease control. Results from three independent vaccine studies are reported here.
Study 1: duration of immunity (exploratory research). The antibody and interferon (IFN) gamma response
induced by an ISCOM (Immuno-Stimulating COMplex)-based EI vaccine (Equip F), was measured in a
group of 4 ponies up to one year after booster immunisation and compared to immunity induced by
equine inﬂuenza virus (EIV) infection. The antibody and IFN gamma responses kinetics were deﬁned
and levels were similar to those induced by experimental EIV infection.
Study 2: accelerated schedule of immunisation (randomised trial). Most EI vaccines require a 4–6 week
interval during the primary two dose course of immunisation, during which time most animals remain
susceptible to EIV infection. The immunogenicity and safety of the ISCOM-based EI + tetanus vaccine
(Equip FT) with a 3-week accelerated immunisation interval was evaluated and compared to the
recommended six-week vaccination interval in order to improve ﬂexibility and to reduce the period of
susceptibility. The antibody responses to the vaccine antigens (tetanus toxoid and EIV) were measured
up to 2 weeks after the ﬁrst booster vaccination (V3). The 3-week accelerated primary course interval
was well tolerated and serology results suggested good immunogenicity against both EIV and tetanus
antigens.
Study 3: efﬁcacy against Florida clade 2 EIV strain (randomised trial). Efﬁcacy against the representative
Florida clade 2 strain A/eq/Richmond/1/07 was also evaluated at the peak of immunity, shortly after 2nd
vaccination (V2). Six ponies were vaccinated with EquipFT according to label (6-week interval between
ﬁrst and second injection) and 6 control ponies received saline injections. Sixteen days after V2 (day 58),
all animals were experimentally infected with A/eq/Richmond/1/07. Clinical signs of disease and virus
shedding were assessed for 14 days and found to be signiﬁcantly reduced in vaccinated animals.
 2015 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Equine Inﬂuenza vaccines have been available since the 1960s.
Despite a widespread use of vaccination and compliance with the
OIE recommendations in Thoroughbred and sport horses since
the late 1980s, EIV is still circulating today and continues to cause
outbreaks of variable size all over the world [1].
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gious and evolving through antigenic drift [2–4]. The OIE expert
surveillance panel on EI vaccines annually reviews laboratory
and epidemiological data about worldwide EIV circulation and
antigenic variation in order to evaluate the EIV antigenic drift,
and to deliver recommendations on vaccine strain composition.
The current recommendation supports inclusion of representatives
of both Florida clade 1 and clade 2 EIV isolates [1]. Vaccine strain
update is essential to optimise the chance of preventing vaccine
efﬁcacy breakdown. In contrast to the well-established and rapid
strain update process for human inﬂuenza vaccines, the substitu-
tion, addition or removal of a strain in current EI vaccines could
take several years. In Europe, only one commercial EI vaccine com-
plies with the last OIE recommendations [1,5]. The inactivated
ISCOM-based EI vaccine reported here is currently being updated
to meet these recommendations. However, modifying an existing
EI vaccine is a lengthy process in order to assure its quality and
efﬁcacy and gain regulatory authority approval. Until an updated
inactivated ISCOM-based EI vaccine is available, it is essential to
optimise the immunisation schedule and to evaluate the efﬁcacy
provided by the non-updated EI vaccine currently commercialised
against current circulating and/or recommended strains.
Promotion of a better vaccine coverage is also a priority to min-
imise the increasing risk of vaccine breakdown [6].
Equip F is an inactivated and ISCOM-based EI vaccine [7],
reviewed in [5,8]. Equip FT is the same vaccine complemented with
the TT antigen. The Equip F ISCOM-based EI vaccine has been
shown to stimulate both humoral and CMI [9] and to provide sig-
niﬁcant protection when tested at the peak of immunity (2 weeks
after the second immunisation) against the representative
outbreak EIV strains A/eq/South Africa/4/03 [9] and
A/eq/Sydney/288-8/07 [10] of the Florida clade 1 sublineage
[11–13]. This EI vaccine contains H3N8 EIV isolates
(A/eq/Borlange/91 and A/eq/Kentucky/98; H3N8; European and
American lineages, respectively), which present antigenic and
genetic differences from the current Florida clade 2 EIV strains cir-
culating in Europe or the Florida clade 1 isolates predominantly
circulating in the US [12,14,15]. It also contains an EIV H7N7 strain
(A/eq/Newmarket/77).
In face of an imminent outbreak of EI, the rapid stimulation of
protective immunity is essential to minimise clinical signs and
limit the spread of disease. The immune response stimulated after
only one immunisation (V1) is usually transient and of low inten-
sity with most EI vaccines [9,16]. While vaccinated horses may
present reduced clinical signs of disease and virus shedding after
a single immunisation, as illustrated in the 2007 Australian out-
break [17], they usually remain susceptible to EIV infection until
several days after the second immunisation (V2) of the primary
course. Most EI vaccines, including Equip F and Equip FT, specify
a 4–6 week interval between V1 and V2. A six weeks interval is
currently recommended for the EI vaccines Equip F and Equip FT
in the UK, where these studies were conducted. During the 2007
Australian EI outbreak, some veterinarians were authorised to con-
duct an accelerated immunisation schedule with a 2 week interval
between V1 and V2 (instead of the 4–6 weeks recommended inter-
val) [18]. A similar approach had also previously been reported
during the South African EI outbreak in 2003 [19]. The SRH anti-
body response, a correlate of protection, induced by the canarypox
virus vector-EI vaccine used during the Australian outbreak was
measured and results supported use of such an accelerated sched-
ule of immunisation [18,20].
We report here results from three independent studies. The ﬁrst
study evaluated the duration of the SRH antibody response and
CMI up to one year post boost immunisation (V3) with the vaccine
Equip F and compared these responses to levels maintained in
ponies one year after experimental infection with the EIV strainA/eq/South Africa/4/03 (exploratory research). In a second study,
the immunogenicity and safety of a 3-week accelerated vaccina-
tion interval for Equip FT was evaluated in order to determine
the potential for this program to reduce the period of susceptibility
to EIV infection during the primary course of immunisation with
this speciﬁc EI vaccine. Finally, in a third study, the ISCOM-based
EI vaccine protective efﬁcacy was measured against the represen-
tative Florida clade 2 strain A/eq/Richmond/1/07, currently recom-
mended for inclusion in EI vaccines by the OIE expert panel [1].2. Materials and methods
2.1. Experimental animals and vaccination protocol
2.1.1. Eligibility criteria
All animals (from 5 months to less than 2 years of age, males
and females) were in good health condition and seronegative for
EIV, with no history of exposure to EIV at the time of the studies.
Ponies enrolled in studies 2 and 3 were also seronegative for TT,
with no history of exposure to Clostridium tetani.2.1.2. Sample size, setting and location
Ponies were enrolled by study site investigators. Eight Welsh
mountain ponies were used for the duration of immunity (DOI)
study (Study 1; conducted at the Animal Health Trust). Due to dif-
ference in treatment schedules, ponies were housed together for
only part of the total study duration. Forty Dartmoor ponies were
used for the accelerated vaccination schedule study (Study 2; con-
ducted at Moredun Scientiﬁc Ltd). Twelve Welsh mountain ponies
were used for the efﬁcacy study (Study 3; conducted at the Animal
Health Trust). Sample size (Studies 2 and 3) were based on power
calculations and to meet the European Pharmacopoeia criteria for
equine inﬂuenza vaccine (inactivated), with no fewer than 6 and
4 horses for the treated and control groups, respectively [21].2.1.3. Intervention
The schedule of vaccination/infection for all studies is presented
in Table 1. Vaccines and placebo were administered by deep intra-
muscular injection in the left neck (2 ml). The EI vaccine Equip F
contained the H7N7 EIV strain A/eq/Newmarket/77 and the
H3N8 EIV isolates A/eq/Borlange/91 and A/eq/Kentucky/98. The
vaccine Equip FT contained the same EIV strains as Equip F and
the immunopuriﬁed tetanus toxoid. The placebo was saline diluent
(NaCl 0.9%).2.1.4. Randomisation and masking
Due to the speciﬁc schedule of immunisation and sampling,
masking was not possible during Study 1. The studies 2 and 3 were
randomised. The randomisation plan was computer-generated by
the study sponsor Veterinary Medicine Research and
Development (VMRD) Biometrics department. Studies 2 and 3
were generalised randomised block studies with one-way treat-
ment structure with the blocking factor based on the treatment
(Studies 2 and 3) and the containment facility room for the exper-
imental infection with EIV (Study 3). Studies 2 and 3 were masked
to eliminate bias; the random treatment allocation plan was
retained by study site Investigators in a secure location.
Personnel at the study site responsible for performing clinical
and general health observations or involved in laboratory assays
were not informed about the allocation of individual animals at
any time during the study. The CMI assay (Study 3) was conducted
by the site investigator. Blood samples for CMI measurement were
anonymised prior to analyses in order to maintain blinding.
Table 1
Study design.
Study 1: duration of immunity
Group Vaccination Treatment1 n = D0 D42 D189
Vaccinates Recommended EIV 4 V1 V2 V3
Outcome: serology D0, D14, D42, D56, D126, D189, D203, D280, D322, D366, D406, D448, D490, D532, D553
Outcome: CMI D0, D14, D42, D56, D126, D189, D203, D406, D553
Infected na Exp. Inf. FC1 4 Exp. Inf. FC1 na na
Outcome: serology D168, D210, D252, D294, D336, D357
Outcome: CMI D0, D14, D210, D336
Study 2: accelerated schedule of vaccination (randomised trial)
Group Vaccination Treatment1 n = D0 D21 D42 D195
T01 Placebo Saline 10 V1 saline V2 Saline V3 Saline V4 Saline
T02 Recommended EIV + TT 10 V1 EIV + TT na V2 EIV + TT V3 EIV
T03 Accelerated EIV 10 na V1 EIV V2 EIV V3 EIV
T04 Accelerated EIV + TT 10 na V1 EIV + TT V2 EIV + TT V3 EIV
Outcome: serology D0, D7, D21, D28, D42, D56, D195 and D209
Study 3: efﬁcacy against A/eq/Richmond/1/07 (randomised trial)
Group Vaccination Treatment1 n = D0 D42 D58
Controls Placebo Saline 6 V1 saline V2 saline Exp. Inf. FC2
Vaccinates Recommended EIV + TT 6 V1 EIV + TT V2 EIV + TT Exp. Inf. FC2
Outcome: serology D-1, D56, D63 and D72
Outcome: CMI D56 and D72
Outcome: clinical signs of diseases D56 to D72
Outcome: EIV shedding D57, D59 to D72
Exp. Inf. FC1 = experimental infection with FC1 A/eq/South Africa/4/03.
Exp. Inf. FC2 = experimental infection with FC2 A/eq/Richmond/1/07.
CMI = cell-mediated immunity.
1 EIV = EquipF; EIV + TT = EquipFT.
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All work involving experimental ponies was performed under
Home Ofﬁce Project Licences and was approved by the Animal
Health Trust’s Ethical Review Committee (Studies 1 and 3;
RPP03/09), by the Moredun Institute Ethical Review Committee
(Study 2) and by the Zoetis Zaventem Ethics Review Assessment
team (Studies 2 and 3). These studies were conducted over a 5 year
period. This report of clinical trials follows the CONSORT 2010
guidelines (Supplementary CONSORT check list and ﬂow chart)
[22,23].
2.2. Viruses and experimental infection with EIV
The EIV strains used in the studies reported here are listed in
the Supplementary Table 1. Viruses were all grown in embry-
onated hen’s eggs, puriﬁed and titrated as described previously
[9]. The EIV strain A/eq/Richmond/1/07 (passage 4 in eggs) was
used for experimental infection in the context of the efﬁcacy study
(Study 3) and was titrated in embryonated hens’ eggs prior to chal-
lenge (day 58). The titre was deﬁned using the method of Reed and
Muench and expressed in EID50 per ml [24]. The ponies were
divided into 2 groups of 6 (3 controls + 3 vaccinates per group)
and experimentally infected by room nebulisation of an infectious
EIV suspension containing a total of 107.81 EID50 EIV strain
A/eq/Richmond/1/07 (ULTRA 2000 nebuliser, DEVibiss, Somerset,
PA, USA) per rooms as described previously [25]. In Study 1 dura-
tion of immunity induced by experimental infection with the EIV
strain A/eq/South Africa/4/03 [19] was compared to immunity
induced by the ISCOM based vaccine. The 4 non-vaccinated and
experimentally infected ponies were previously described [9].
2.3. Efﬁcacy study (Study 3): clinical signs of disease (pre-speciﬁed
analysis)
Clinical examinations were performed daily on each pony from
day 56 (2 days prior to challenge) until day 72(challenge + 14 days) for the occurrence of clinical signs associated
with EI as previously described [25,26]. Rectal temperatures
greater than 38.8 C were regarded as pyretic. Abnormal nasal
discharge were deﬁned as nasal discharge score P3, as nasal dis-
charge scored 62 were recorded in several ponies immediately
prior to experimental infection. The sickness score after experi-
mental infection with EIV was calculated using the daily score
for each clinical sign according to the formula previously reported
[26]: sickness score = (2 ⁄ score RT) + score nasal discharge + score
cough + 2 ⁄ (score dyspnoea + anorexia + depression). This calcula-
tion was performed by Animal Health Trust to be consistent with
previously published studies. Ponies developing long lasting
(>3 days) clinical signs after experimental infection with EIV were
treated to control secondary bacterial infection (detailed in
Supplementary Table 2).
2.4. Efﬁcacy study (Study 3): virus excretion (pre-speciﬁed analyses)
Nasopharyngeal swabs were taken from each pony on day 1,
day 57 and daily for 14 days from day 59 to day 72, excluding
day 58 (challenge infection). Swabs were processed in 5 ml of virus
transport medium (PBS, 200U/ml streptomycin, 150U/mL peni-
cillin, 5 mg/ml amphotericin B and 600 mg/ml tryptone phosphate
broth, all supplied by Sigma–Aldrich Co) and stored around 70 C
prior to analysis with 3 different assays: EIV nucleoprotein
enzyme-linked immunosorbent assay (EIV NP ELISA), EIV nucleo-
protein reverse transcriptase polymerase chain reaction (EIV NP
RT-PCR) and embryonated hens’ egg titration. The EIV NP ELISA
measures equine inﬂuenza virus proteins, EIV NP qRT-PCR results
show the presence of genetic material and the titration in embry-
onated eggs assesses the presence of live infectious virus. The EIV
NP-ELISA results were calculated as x-fold background with posi-
tive results deﬁned as P2, for standardisation results are
expressed as a ratio; x-fold background assay/x-fold background
plate positive control. The EIV NP quantitative RT-PCR results were
expressed as number of EIV NP RNA copy per 2 ll of swab extract,
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qRT-PCR threshold was deﬁned to provide a sensitivity of 95.8%
[25]. Infectious EIV was titrated in embryonated hens’ eggs only
if the EIV NP ELISA and/or qRT-PCR gave a positive result. Results
are expressed as log EID50/ml [24] of swab extract as previously
described [26]. If at least one out of three tests described above
was positive, it was concluded that the virus isolation test was
positive.
2.5. Serology (pre-speciﬁed analyses)
Serum samples were analysed by SRH assays against several EIV
antigens (Supplementary Table 1). The sampling schedule is pre-
sented in Table 1. SRH antibody titres were expressed as the area
of haemolysis (mm2). An increase of at least 25 mm2 or 50% in
the area of the zone of haemolysis was regarded as signiﬁcant.
European Pharmacopoeia reference serum standards Eu N/1/93
E0850021 (A/equine2/Newmarket/1/93) and Eu SA/4/03
Y0000712 (A/equine2/South Africa/4/2003) were used as positive
control sera (data not shown) and used for standardisation. The
ToBI test was established according to [27,28]. Brieﬂy, ELISA wells
were coated with a goat anti-tetanus polyclonal antibody (Abd
Serotec), in carbonate/bicarbonate buffer (Sigma–Aldrich Co.),
and incubated at 37 C overnight. Starting at a 1:10 dilution, serum
samples were titrated across a separate 96 well plate in doubling
dilutions in blocking buffer (0.5% BSA in PBS; Sigma–Aldrich Co.).
A reference standard (Equine Tetanus antitoxin, 60/013, NIBSC)
was used to generate a standard curve. Serum from a group of
unvaccinated ponies was pooled and used as a negative control.
Tetanus toxoid diluted in PBS was added to each well of diluted
serum and incubated at 37 C overnight. Following incubation,
ELISA wells were subsequently blocked for 1 h at 37 C. The serum
sample/tetanus toxoid suspension was then added to each well
and incubated for 2 h at 37 C. A tetanus toxoid mouse monoclonal
antibody (HYB278-01: Abcam) diluted in blocking buffer was then
added to each well and incubated for 1 h at 37 C. Finally, goat
anti-mouse horseradish peroxidase conjugated antibody (Dako)
diluted in blocking buffer was added to each well and incubated
for 45 min at 37 C. Between each antibody step, plates were
washed 4 times with 0.05% PBS-Tween per well. TMB (3,30,5,50-te
tramethylbenzidine) peroxidase substrate (KPL) was added to each
well and incubated at room temperature for 10 min, before addi-
tion of H2SO4 to stop the reaction. Plates were read at 450 nm
and sample titres were calculated against the standard curve [29].
2.6. Measure of IFN gamma synthesising cells (pre-speciﬁed analysis)
Peripheral blood mononuclear cells were puriﬁed from hep-
arinised blood samples (Table 1) by centrifugation on
Ficoll-Hypaque (Amersham Biosciences, Uppsala, Sweden). The
frequency of EIV-speciﬁc T-lymphocytes synthesising IFN gamma
was measured as previously described [25,30]. The percentage of
virus speciﬁc IFN gamma synthesis was calculated according to
the formula (% of cells synthesising IFN gamma after virus stimula-
tion)  (% of cells synthesising IFN gamma after culture in medium
alone).
2.7. Statistical analysis
Study 1: due to limitations in terms of animals numbers, ran-
domisation and difference in the treatment schedule, statistical
analyses performed for this study were limited to a Student’s t-test.
Studies 2 and 3: statistical analysis was carried out by Zoetis using
the Statistical Analysis System (SAS Release 9.2, SAS Institute, Cary,
NC, USA)) procedures with PROC MIXED used for analysis of quan-
titative, continuous data and either PROC GLIMMIX or PROCMULTTEST used for analysis of qualitative, categorical data.
Power calculations and the PROC MIXED procedure are detailed
in the Supplementary data. The experimental unit for analysis
was the individual animal. Study 2 was a generalised randomised
block design with one-way treatment structure with the blocking
factor based on pen. Signiﬁcance and non-inferiority were tested
for serology results. Study 3 had a generalised randomised block
design with one-way treatment structure with the blocking factor
based on challenge room and vaccination schedule. If the EIV titra-
tion in embryonated hens’ eggs was not performed (EIV NP ELISA
and NP qRT-PCR negative), a score of 0 was assigned for conduction
of the statistical analysis, the calculation of average and standard
deviation. The percentage of days with positive virus isolation
was compared using a 2-tailed Fisher’s Exact test.
3. Results
3.1. Safety
All animals were observed for 4 days after each vaccination for
the presence of post-immunisation systemic (pyrexia) or site reac-
tion. The vaccine and placebo were well tolerated. Two ponies
showed elevated rectal temperatures (>38.8 C) after vaccine
administration (Study 1); one pony was pyretic for one day after
V1 and V2, and for 4 days after V3. The second pony was pyretic
for 2 days after V2 only. Only one pony showed site reaction for
one day only (T04 group in Study 2). No other adverse reactions
were observed.
3.2. Duration of immunity (Study 1)
All vaccinated ponies developed an SRH antibody response
against all EIV antigens tested after V1 (Fig. 1A). This response
decreased rapidly between V1 + 2 weeks and V2 (day 42). The
SRH antibody response was boosted after V2 in all 4 ponies, but
decreased below 25 mm2 between V2 + 2 weeks and V3 (day
189) for 3 out of 4 ponies. Only one pony maintained levels of
SRH antibodies >85 mm2. The SRH antibody response was strongly
boosted after V3 in all 4 ponies. These levels of SRH antibodies
were above the threshold described to provide protection against
clinical signs of disease and virus shedding after infection with
EIV [31]. A rapid decrease in SRH antibody titres was measured
during the 16 weeks following V3 + 2 weeks (e.g., from
188 ± 29.1 mm2 at V3 + 2 weeks to 79.8 ± 11.4 mm2 when tested
against A/eq/South Africa/4/03). After 18 weeks, the decrease was
slower (e.g., from 79.8 ± 11.4 mm2 at V3 + 18 weeks to
53 ± 22.3 mm2 when tested against A/eq/South Africa/4/03 at
V3 + 52 weeks). SRH antibodies were still detectable 1 year after
V3 at a level similar to the SRH antibody measured in ponies,
one year after experimental infection with A/eq/South
Africa/4/03 (p-value = 0.43). Similar results were obtained when
the EIV strains A/eq/Sydney/288-8/07 and A/eq/Newmarket/2/93
were used as antigens (Supplementary Table 3). All vaccinated
ponies developed an EIV-speciﬁc IFN gamma response after V1, a
response that was boosted after V2 and V3 (Fig. 1B). A year after
V3 or 48 weeks after experimental infection (day 553 and day
336, respectively), the EIV-speciﬁc IFN gamma response was
detectable in all vaccinated ponies (4.5% ± 2.3) and EIV infected
ponies (1.6% ± 1.3). The difference was not signiﬁcant
(p-value = 0.07).
3.3. Accelerated schedule of immunisation (Study 2)
The accelerated schedule of vaccination (V1 and V2, 3 weeks
apart) was compared to the conventional schedule (V1 and V2,
6 weeks apart). Levels of EIV-speciﬁc (A/eq/Borlange/91 and
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Fig. 1. Duration of immunity: (A) kinetics of SRH antibody response tested against A/eq/South Africa/4/03 in ponies vaccinated with Equip-F, from V1 (day 0) to V3 + 1 year
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2 weeks after V2 (day 56), and 2 weeks after V3 (day 209) in order
to evaluate the impact of the accelerated schedule of vaccination
on the humoral immune response. Group descriptions are pre-
sented in Table 2 and results illustrated in Figs. 2 and 3
(Supplementary Table 4).
For the EIV antigens non-inferiority of the SRH antibody
responses in the accelerated interval (T03 and T04) as compared
to the conventional interval (T02) could be demonstrated 2 weeksTable 2
Accelerated study (Study 2), SRH antibody response to A/eq/Borlange/91 and A/eq/Kentuck
Group Vaccination Treatment1 n = D0 D7 D21
SRH antibody response to A/eq/Borlange/91 (European lineage)
T01 Placebo Saline 10 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0
T02 Recommended EIV + TT 10 0.0 ± 0.0 0.0 ± 0.0 na
T03 Accelerated EIV 10 na na 0.0 ± 0
T04 Accelerated EIV + TT 10 na na 0.0 ± 0
SRH antibody response to A/eq/Kentucky/98 (American lineage)
T01 Placebo Saline 10 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0
T02 Recommended EIV + TT 10 0.0 ± 0.0 0.0 ± 0.0 na
T03 Accelerated EIV 10 na na 0.0 ± 0
T04 Accelerated EIV + TT 10 na na 0.0 ± 0
1 EIV = EquipF; EIV + TT = EquipFT; n = number of animals per group. FC2 = Florida cafter V2 (day 56 for T02 and day 35 for T03 and T04) for both anti-
gens. Two weeks after V3 (day 209 for T02 and day 188 for T03 and
T04), non-inferiority of the accelerated interval was demonstrated
for Kentucky/98 only. At this timepoint the SRH antibody response
to A/eq/Borlange/91 in group T02 was signiﬁcantly higher than in
group T03 (p-value = 0.013) and in group T04 (p-value = 0.0323).
At the peak of immunity after both V2 and V3, in all vaccinated
groups, SRH antibody levels were well above 85 mm2 with the
exception of one pony in group T04. This one pony had an SRHy/98. Results are expressed as average means ± standard deviation. Test units = mm2.
D28 D42 D56 D195 D209
.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
na 40.5 ± 36.8 142.8 ± 24.3 51.7 ± 27.0 191.1 ± 19.9
.0 0.0 ± 0.0 34.2 ± 38.2 164.1 ± 26.3 49.1 ± 23.3 155.7 ± 21.6
.0 0.0 ± 0.0 60.8 ± 44.7 156.5 ± 37.6 33.9 ± 33.2 168.2 ± 23.7
.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
na 39.3 ± 24.7 124.3 ± 26.4 27.8 ± 16.1 178.5 ± 22.5
.0 7.6 ± 24.1 46.5 ± 40.4 148.2 ± 32.3 40.8 ± 21.3 164.6 ± 28.3
.0 0.0 ± 0.0 68.7 ± 43.7 140.4 ± 40.8 32.8 ± 26.2 172.7 ± 39.0
lade 2 sublineage.
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had increased to 155.7 mm2 after V3. At Day 56, 36.7% and 50%
of the vaccinated ponies had SRH responses above 150 mm2
against A/eq/Borlange/91 and A/eq/Kentucky/98, respectively. At
Day 209 this was the case for 73.3% and 80% of the vaccinated
ponies respectively. Immediately prior to V3 (day 195), only one
vaccinated pony reached SRH levels above 85 mm2, and 30% and
23% were below 25 mm2 against A/eq/Kentucky/98 and
A/eq/Borlange/91, respectively. However, SRH antibody levels
were similar between groups.
The TT-speciﬁc antibody response was detectable in groups T02
and T04 after V1. ToBI titres were strongly boosted after V2 and
remained detectable up to day 209 of the study (Fig. 3). ToBI least
squares means titres were 86.3 IU/mI for T02 and 45.9 IU/ml for
T04 after V2 (day 56) and 2.6 IU/ml for T02 and 2.2 IU/ml for T04
on day 209. Non-inferiority of the tetanus antibody response in
group T04 as opposed to group T02 could not be shown for eitherof the time-points. On Day 56 the TT-speciﬁc antibody response
was signiﬁcantly higher in T02 than in T04 (p-value = 0.0038). No
signiﬁcant difference was measured on day 209 (p-value = 0.5735)
(Fig. 3B).
3.4. Efﬁcacy against A/eq/Richmond/1/07 (Study 3)
Vaccinated ponies were experimentally infected at the peak of
immunity (V2 + 16 days; day 58) with the EIV strain
A/eq/Richmond/1/07. At the time of challenge, ponies showed high
levels (175.1 ± 1.9 mm2) of cross-reactive SRH antibody when
tested against the challenge strain (Table 3 and Supplementary
Table 5). Vaccinated ponies also showed an increased EIV-speciﬁc
IFN gamma response (1.17% ± 0.45) when compared with control
ponies (0.12% ± 0.03; Supplementary Table 6).
Post challenge rectal temperatures were signiﬁcantly lower for
the vaccinated ponies on days 2, 4, 5, 6 and 9 post experimental
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Table 3
Efﬁcacy study (Study 3), SRH antibody response to A/eq/Borlange/91, A/eq/Kentucky/98 and A/eq/Richmond/1/07. Results are expressed as average means ± standard deviation.
Test units = mm2.
Group Vaccination Treatment1 n = D-1 D56 D63 D72
SRH antibody response to A/eq/Borlange/91 (European lineage)
Controls Placebo Saline + C 6 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 69.7 ± 55.7
Vaccinates Recommended EIV + TT 6 0.0 ± 0.0 154.0 ± 7.4 130.0 ± 7.7 152.7 ± 22.0
SRH antibody response to A/eq/Kentucky/98 (American lineage)
Controls Placebo Saline + C 6 0.0 ± 0.0 0.0 ± 0.0 7.4 ± 18.1 129.9 ± 61.4
Vaccinates Recommended EIV + TT 6 0.0 ± 0.0 134.73 ± 6.9 120.62 ± 9.4 141.32 ± 23.0
SRH antibody response to A/eq/Richmond/1/07 (FC2)
Controls Placebo Saline + C 6 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 133.6 ± 32.1
Vaccinates Recommended EIV + TT 6 0.0 ± 0.0 175.1 ± 1.9 147.1 ± 4.5 178 ± 32.2
n = number of animals per group. Eff. study = efﬁcacy study. FC2 = Florida clade 2 sublineage.
1 EIV = EquipF; EIV + TT = EquipFT; C = challenge.
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nated ponies and 63.0 ± 19.9 for the controls (Fig. 4B). Coughing
and abnormal nasal discharge were reduced in vaccinated ponies
on day 8 and day 9 post experimental infection, respectively. In
addition, the percentage of days with abnormal health post chal-
lenge was less for the vaccinated ponies when compared with
the controls (respectively: coughing, 17.1% and 66.5%
(p-value = 0.0307); dyspnoea, 0.0% and 8.5% (p-value = 0.0189);
nasal dischargeP3, 3.9% and 39.7% (p-value = 0.0122)). No pyrexia
was observed in the vaccinates whereas all the controls were pyre-
tic for a total of 1–4 days. No anorexia, depression and dyspnoea
were observed in the vaccinates whereas respectively 1 (1 day), 2
(1–2 days) and 4 (1–5 days) controls showed these clinical obser-
vations. Clinicals signs of disease are summarised in the
Supplementary Table 7. After challenge, 5 out or 6 controls and 1
out of 6 vaccinates had to be treated to control the severity of dis-
ease most probably caused by secondary bacterial infections. The
decision to treat animals was made by a veterinarian who was
blinded to vaccine status.
Three different assays (NP ELISA, qRT-PCR and embryonated
hens’ egg titration) were performed to assess virus excretion
(Supplementary Table 7). No EIV shedding was measured when
samples from vaccinates were tested with the EIV NP ELISA orthe titration in embryonated hens’ eggs (Fig. 4D). EIV shedding
was detected in vaccinates qRT-PCR on days 2 (5 out of 6 ponies),
on days 3 to 4 (one pony) and from days 8 to 10 (one pony) post
experimental infection (Fig. 4C). All control ponies shed EIV during
5 to 7 days. Quantitative qRT-PCR test results demonstrated that
from days 3 (day 61) to 7 (day 65) post experimental infection, vac-
cinated ponies shed signiﬁcantly less virus than the control group.
The percentage of days with positive virus isolation was signiﬁ-
cantly reduced in the vaccinated group (6.8% ± 4.84), when com-
pared with the control group (41.6% ± 2.2; p-value = 0.0054;
2-tailed Fisher’s Exact).
4. Discussion
The level of protection against EI has been correlated to the SRH
antibody titre at the time of infection [7,31]. However, SRH anti-
body levels ﬂuctuate over time. In this context, it is important to
measure and understand the duration of immunity induced by EI
vaccines in order to better identify and delineate periods of suscep-
tibility or efﬁcient protection. The overall kinetics of the SRH anti-
body response induced by the ISCOM-based EI vaccine reported
here followed a conventional pattern, as described for a previous
ISCOM-based EI vaccine [32] and other type of EI vaccines as
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Long-term stimulation and maintenance of CMI after
ISCOM-based EI vaccine has not been previously reported.
Most vaccinated ponies are likely to remain susceptible to EIV
infection until protective levels of antibodies are reached,
10–14 days after the second immunisation (V2). Therefore, a rea-
sonable reduction of the recommended 6 weeks interval between
V1 and V2 should improve overall protection by shortening the
period of susceptibility. The 3-week accelerated primary course
interval showed good immunogenicity in the limited time frame
studied here. This result suggests the potential for a more ﬂexible
use of the ISCOM-based EI-TT vaccine, which could allow a reduc-
tion of the period of susceptibility to EIV infection during the pri-
mary course of immunisation, and also conﬁrms previous results
with this type of EI vaccine [33]. The accelerated schedule would
also be beneﬁcial if implemented in face of an imminent outbreak
when immunity needs to be rapidly boosted and mobilised, as
demonstrated with the canarypox virus EI vaccine during the
2007 Australian outbreak [20]. Further studies are necessary to
evaluate the potential impact of the accelerated primary immuni-
sation course on the duration of immunity.In Study 2, non-inferiority of the tetanus antibody response in
the accelerated EIV + TT vaccination schedule group (T04) as
opposed to the recommended EIV + TT vaccination schedule
(T02) could not be shown for neither of the time-points. This could
partly be explained by the heterogeneity of the immune responses
which was higher than assumed initially. Therefore this study was
underpowered for some of the non-inferiority test. On Day 56 the
TT-speciﬁc antibody response was signiﬁcantly higher in T02 than
in T04. However, TT-speciﬁc antibody titres in both groups were
well above historical protective threshold (i.e., 0.02 IU/ml) against
tetanus [28]. No signiﬁcant difference was measured on day 209
(Fig. 3B). These results tend to indicate than an accelerated sched-
ule of vaccination should not impact vaccine protection against
tetanus.
On day 56 (V2 + 2 weeks) and day 209 (V3 + 2 weeks) of the
Study 2, around 50% and 80% of the vaccinated ponies had SRH
levels above 150 mm2. Vaccinated ponies (V2 + 16 days) with sim-
ilar protective levels of SRH antibody [7,31] were challenged with
the representative Florida clade 2 EIV strains A/eq/Richmond/1/07
(Study 3). This EIV strain is recommended by the OIE expert panel
on inﬂuenza vaccine for inclusion in EI vaccines and has been
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EI vaccine signiﬁcantly reduced the clinical signs induced by the
EIV strain A/eq/Richmond/1/07. Vaccine-induced sterilizing immu-
nity (as deﬁned by an absence of clinical signs, virus shedding and
seroconversion) is difﬁcult to achieve and requires elevated anti-
body titres. One vaccinated pony did not shed EIV or serocon-
verted, which could indicate a case of sterilizing immunity. This
pony had also the second highest SRH antibody titre to
A/eq/Richmond/1/07 at the time of infection. Two other vaccinated
ponies showed no seroconversion against any of the antigens
tested at the end of the study (14 days post experimental infection)
but shed EIV for at least one day. Two out of 6 control ponies had
no SRH antibody response to A/eq/Richmond/1/07 or
A/eq/Borlange/91, when measured 14 days after experimental
infection, but showed SRH antibody titre to A/eq/Kentucky/98
<100 mm2 on D14 post infection, supporting a slower seroconver-
sion when compared with other animals. When measured 14 days
after experimental infection, SRH levels between the control and
vaccinated groups were not statistically different for the antigens
A/eq/Kentucky/98 and A/eq/Richmond/1/07. However, SRH anti-
body titres were signiﬁcantly different when tested against the
European vaccine strain A/eq/Borlange/91 (Supplementary
Table 5). This difference was explained by a low SRH antibody titre
against A/eq/Borlange/91 (69.7 ± 55.7 mm2) in control ponies
experimentally infected with A/eq/Richmond/1/07, when com-
pared with 152.7 ± 22.0 mm2 in vaccinated and challenged ponies.
This result tends to indicate that in the absence of previous expo-
sure to a European vaccine strain (i.e., naïve control animals), the
level of cross-reactive antibody to an EIV strain of the European
lineage induced by experimental infection with a Florida clade 2
EIV isolate was limited. These may reﬂect the antigenic difference
between these strains. In vaccinated ponies, the cross-reactive
antibody response to the European strain A/eq/Borlange/91 was
boosted after experimental infection with A/eq/Richmond/1/07.
The protective immunity induced by boost immunisation
decreases in time and a period of susceptibility (or immunity
gap) is usually observed between V2 and the ﬁrst boost immunisa-
tion (V3) [35]. The level of SRH antibody measured in ponies
immediately prior to V3 was low. In general, this could suggest
that protection against infection with EIV may be reduced. This
result conﬁrms recent ﬁeld data. Low SRH levels were measured
in the week preceding V3 after immunization with most commer-
cial EI vaccines [16,36].
Several cases of EI vaccine breakdown have been recently
reported in horses (all vaccine brands involved), in the weeks pre-
ceding V3 or several months after the last boost immunization
[37]. This ﬁeld data supports results from a recent study showing
that young EI vaccinated ponies were susceptible to EIV infection
and transmitted EIV when experimentally infected with
A/eq/Richmond/1/07, 12 weeks after V2 (day 120) [34].
Several studies have investigated the immunity gap [38–40].
Those studies showed signiﬁcant reduction of clinical signs of dis-
ease and virus shedding in animals immunized with some of the EI
vaccines currently commercialised. However, vaccinates still shed
virus for several days. In those studies, the EIV strains used for
challenge infection (A/eq/Sussex/89, A/eq/Kentucky/91 and
A/eq/Kentucky/9/95) were relatively close to the vaccine strains
of the corresponding lineage (A/eq/Newmarket/2/93-A/eq/Kentuc
ky/94 or A/eq/Newmarket/1/93). Divergence between vaccine
and challenge strains has been shown to affect the level of virus
shedding [41,42] and therefore needs to be taken into account
when evaluating EIV shedding after challenge.
SRH levels a year after vaccination with the ISCOM-based EI
vaccine were similar to the SRH antibody response detected in
ponies one year after experimental infection with A/eq/South
Africa/4/03. Those same four ponies were signiﬁcantly protectedagainst clinical signs of disease and virus shedding when
re-infected with A/eq2/Sydney2888–8/07, 18 months after initial
contact with A/eq2/South Africa/4/03. At this time, ponies showed
little or undetectable SRH antibody titre [10]. It is likely that pro-
tection in absence of antibodies involved CMI stimulation, which
efﬁciently supports or replaces protection induced by antibodies
[10,43,44]. Stimulation of IFN gamma, a CMI marker, was previ-
ously demonstrated after immunization with ISCOM and
ISCOMatrix EI [9,45,46]. This result was conﬁrmed here. The IFN
gamma responses, measured a year after boost immunisation with
the ISCOM-based EI vaccine were similar to levels detected in
ponies experimentally infected with A/eq/South Africa/4/03 at a
similar time point.5. Conclusion
It is encouraging to note that SRH antibody and CMI levels mea-
sured one year after V3 were similar to levels evaluated in a group
of ponies one year after experimental infection with the
A/eq/South Africa/4/03 strain. However, yet unidentiﬁed differ-
ences in immune responses induced by natural EIV infection and
immunization with an inactivated EI vaccine may inﬂuence
long-term protection against EI. The 3-week accelerated primary
course interval was well tolerated, showed good immunogenicity
during the timeframe of the study, and supports a potential to
use the ISCOM-based EI vaccine to reduce the period of susceptibil-
ity usually observed during the primary course of immunisation.
The strains contained in the ISCOM-based EI vaccine are no longer
in line with the OIE recommendations. This speciﬁc vaccine is cur-
rently being updated to meet these recommendations. Results pre-
sented here conﬁrm efﬁcacy of the currently commercialised
ISCOM-based EI vaccine tested in this study, especially in condi-
tions where EI immunity is rapidly boosted prior to a potential
contact with EIV (e.g., in the face of an EI outbreak or shortly before
contact with new horses, such as races or events). However, the
vaccine efﬁcacy, measured in study 3 close to the peak of immunity
(i.e., 16 days post V2), may ﬂuctuate in time. As for all EI vaccines,
it is likely that future strain updates will improve overall protec-
tion and will reduce the risk of vaccine under performance, espe-
cially at the early stage of the immunisation schedule.
Vaccination remains one of the most effective methods to prevent
or limit the impact of EI, but commercially available EI vaccines
should be updated. In the meantime, increased use of EI vaccines
in susceptible horse populations (resident and travelling horses)
as well as better vaccine coverage and identiﬁcation of poor vac-
cine responders would result in improved protection.Conﬂict of interest
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